Development · 28 Oct 2026

Cipla reported a 35% year-on-year decline in consolidated net profit in Q2 FY27, with profit after tax of ₹878 crore.

3 publishers have reported this development. Each act of reporting is below, cited.

The record

business-standard.com27 Oct 2026

Cipla reported a 35 percent year-on-year decline in net profit to Rs 878 crore for the second quarter ended September.

indiatimes.com27 Oct 2026

Cipla Q2 profit declines 35%.

thehindubusinessline.com27 Oct 2026

Cipla

₹1,365.60

▲ +1.16%

Close (EOD), as of 28 Oct 2026 · source

Cipla: results, dividends, orders, the full cited record →

More on Cipla

Cipla Ltd. expects new launches to support its margin improvement from fiscal 2028 onwards, as it expects sequential profit growth to continue for two more quarters according to its earnings conference call on Tuesday.

28 Oct 2026 · 1 publisher

Cipla is targeting a first wave launch of its in-licensed Keytruda biosimilar ‘QL2107’ in the US market post patent expiry in 2029.

28 Oct 2026 · 1 publisher

Cipla secured approvals for two key respiratory products, gVentolin and gAdvair, in H1 FY27.

28 Oct 2026 · 1 publisher

Cipla expects to reach $1 billion in annual revenue in the United States by year-end, driven by its existing pipeline.

28 Oct 2026 · 1 publisher

Cipla's September-quarter earnings were impacted by a high base in the US business and weak sales of active pharmaceutical ingredients, leading to a softer year-on-year performance.

28 Oct 2026 · 1 publisher

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.